Share ownership Monte Rosa Therapeutics, Inc.

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 21/08/2026 +03			5-day change	1st Jan Change
14.30 ^USD	-3.25%		-7.74%	-8.80%

08-06	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, vs. FactSet Est of $12.9M	MT

Share class: Monte Rosa Therapeutics, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	85,313,401	84,835,029 ( 99.44 %)	0	99.44 %

Major shareholders: Monte Rosa Therapeutics, Inc.

Name	Stocks	%	Valuation
T. Rowe Price Associates, Inc. (IM) 10.49 %	8,861,282	10.49 %	146 M $
T. Rowe Price International Ltd. 10.49 %	8,861,171	10.49 %	146 M $
NEA Management Co. LLC 7.922 %	6,692,298	7.922 %	111 M $
BlackRock Advisors LLC 7.631 %	6,446,295	7.631 %	106 M $
Dimension Management LP 6.704 %	5,663,265	6.704 %	94 M $
TCG Crossover Management LLC 5.471 %	4,622,151	5.471 %	76 M $
TCG Crossover Management LLC 5.471 %	4,622,151	5.471 %	76 M $
Vestal Point Capital LP 5.445 %	4,600,000	5.445 %	76 M $
Vestal Point Capital LP 5.445 %	4,600,000	5.445 %	76 M $
BVF, Inc. 5.28 %	4,460,886	5.28 %	74 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	136.1%
Others	12%
State Street Corp.	4.42%
Individuals	1.05%
Alphabet, Inc.	0.44%
Manulife Financial Corp.	0.23%
Schweizerische Nationalbank	0.11%
SEI Investments Co.	0.06%
Governments	0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	132.53%
United Kingdom	13.3%
Switzerland	4.26%
Australia	1.34%
Individuals	1.05%
Germany	0.94%
Canada	0.58%
Ireland	0.23%
Hong Kong	0.07%
Cayman Islands	0.05%
Luxembourg	0.03%
China	0.03%
Singapore	0.02%
Norway	0.01%

Based on 1000 largest holdings

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the bodyâ€™s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Employees

173

Sector

Biotechnology & Medical Research

More about the company